Shanghai Bao Pharmaceuticals Co., Ltd. (HKG:2659)

HKG:2659 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023
Revenue	46.66	6.16	6.93
Revenue Growth (YoY)	-	-11.11%	-
Cost of Revenue	0.95	1.14	0.15
Gross Profit	45.71	5.02	6.78
Selling, General & Admin	111.97	115.54	47.58
Research & Development	245.48	250.73	132.55
Other Operating Expenses	-3.48	-1.77	-6.68
Operating Expenses	353.97	364.51	173.45
Operating Income	-308.26	-359.49	-166.66
Interest Expense	-5.22	-4.56	-3.66
Interest & Investment Income	6.44	4.65	7.9
Earnings From Equity Investments	-0.48	-0.61	-0.92
Currency Exchange Gain (Loss)	0.44	1.19	2.97
Other Non Operating Income (Expenses)	-18	-5.57	-
EBT Excluding Unusual Items	-325.08	-364.38	-160.37
Gain (Loss) on Sale of Assets	-0.08	-0.08	-0.03
Pretax Income	-380.24	-364.46	-160.4
Income Tax Expense	-	-0.02	-0
Net Income	-380.24	-364.43	-160.4
Net Income to Common	-380.24	-364.43	-160.4
Shares Outstanding (Basic)	56	54	51
Shares Outstanding (Diluted)	56	54	51
Shares Change (YoY)	-	5.82%	-
EPS (Basic)	-6.75	-6.81	-3.17
EPS (Diluted)	-6.75	-6.81	-3.17
Free Cash Flow	-248.81	-338.06	-276.58
Free Cash Flow Per Share	-4.42	-6.32	-5.47
Gross Margin	97.95%	81.49%	97.85%
Operating Margin	-660.67%	-5835.80%	-2404.96%
Profit Margin	-814.93%	-5916.12%	-2314.50%
Free Cash Flow Margin	-533.26%	-5487.91%	-3991.02%
EBITDA	-277.6	-329.76	-146.12
D&A For EBITDA	30.66	29.73	20.55
EBIT	-308.26	-359.49	-166.66

Source: S&P Global Market Intelligence. Standard template. Financial Sources.